小细胞肺癌多基因组学研究进展

Progress of multi-genomics in small cell lung cancer

多基因组学测序研究开启了非小细胞肺癌(NSCLC)的靶向精准治疗时代,然而,小细胞肺癌(SCLC)基因组学研究较少,目前其发病机制、驱动基因尚未明确。组织获取困难、致瘤因素复杂、疾病进展迅速、化疗耐药机制不清是SCLC转化研究难以突破的主要原因。因此,多基因组学测序研究对于全面解析SCLC的基因组特征、明确肿瘤驱动基因以及探索药物治疗靶点显得尤为重要。文章分析了SCLC已发表的多基因组学等相关研究结果,并对其临床相关性等进行了初步探讨。

Multi-genomic sequencing research has opened the era of targeted precision medicine for non-small cell lung cancer(NSCLC).However,there are few genomic researches on small cell lung cancer(SCLC),and its pathogenesis and driver genes have not been clarified.Difficulties in obtaining tumor tissues,complex tumorigenic factors,rapid disease progression,and unclear mechanism of chemotherapy resistance are the main reasons for the hardly breakthrough in SCLC translational research.Therefore,multi-genomic sequencing research is particularly crucial for the integrated analysis of the genomic characteristics,identification of cancer driver genes and exploration of drug therapeutic targets of SCLC.This article analyzes the results of various published SCLC multi-genomic studies,and makes a preliminary discussion on their clinical relevance.